On October 6, GRAIL, Inc. rose 5.14% in regular trading, trading at $165.125 per share, with Turnover of $16.7994 million. The movement continues to be driven by the positive vote from the FDA's Molecular and Clinical Genetics Devices Panel on the Galleri multi-cancer early detection test. The panel voted 10:0 in favor of safety, 6:4 in favor of efficacy, and 7:2 in favor of the benefit-risk profile. The PATHFINDER 2 study also showed that Galleri, when combined with standard screening, increased cancer detection rates by 6.5 times, with 71% of newly detected cancers in stages I through III. Although the panel's recommendation is not binding on the FDA, market sentiment has remained optimistic, as reflected by UBS raising its price target from $105 to $175.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)